Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...
TDP-43 CYTOPE ® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting...
Novo Nordisk’s Phase 2 data for coramitug supports ongoing Phase 3 CLEOPATTRA clinical trial in patients with ATTR amyloidosis with cardiomyopathy Coramitug is being developed by Novo...
Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease Fast Track Designation recognizes the...